Finasteride Not Effective in Older Women With Androgenetic Alopecia

This study found that finasteride improves scalp hair growth in men with male pattern hair loss by reducing scalp dihydrotestosterone levels, but it did not benefit postmenopausal women with female pattern hair loss.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This article discusses the prevalence and patterns of androgenic alopecia in men and women, highlighting its progression and differences in hair loss distribution between the sexes, but reports no new data.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.